Abstracts tagged "Infection"

Abstract Number: 0224 • ACR Convergence 2023
Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Emily Kowalski¹, Xiaosong Wang¹, Naomi Patel², Yumeko Kawano¹, Claire Cook², Kathleen Vanni¹, Grace Qian¹, Katarina Bade³, Shruthi Srivatsan², Zachary Williams², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: As initial COVID-19 infections become nearly ubiquitous and the available prevention and treatment strategies evolve, patients with systemic autoimmune rheumatic diseases (SARDs) may be…
Abstract Number: 0990 • ACR Convergence 2023
Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry
Kelly Gavigan¹, Esteban Rivera², Odette Kolenky³, Cassie Clinton⁴, Emily Holladay⁴, David Curtis⁵, Laura Stradford⁶, Jeffrey Curtis⁴, W. Benjamin Nowell⁶, Christian Curtis⁷ and Michael George⁸, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, Long Island City, NY, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, San Francisco, CA, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Illumination Health, Birmingham, AL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
Abstract Number: 1670 • ACR Convergence 2023
Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae
CAMILA CAETANO¹, Tamiris Azamor¹, Nikki M. Meyer¹, Cassandra Calabrese², Leonard Calabrese², Nicolas Piuzzi³, M. Elaine Husni², Suan-Sin Foo¹ and Weiqiang Chen¹, ¹Cleveland Clinic / Infection Biology Program, Global Center for Pathogen Research and Human Health, Lerner Research Institute, Cleveland, OH, ²Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ³Cleveland Clinic / Department of Orthopedic Surgery, Cleveland, OH
Background/Purpose: Patients with underlying immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have a higher susceptibility to severe COVID19…
Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Arthur Mageau¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden / Internal Medicine Unit, Hopital Bichat, Paris, France, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…
Abstract Number: 0199 • ACR Convergence 2023
Experience in Real-World Conditions of the Effectiveness of the Vaccine Against Herpes Zoster Virus
Laura Mas Sanchez¹, Pablo Francisco Muñoz Martínez², Elena Grau Garcia³, Alba Maria Torrat Noves³, Daniel Ramos Castro³, Carmen Riesco Barcena³, Anderson Victor Huaylla Quispe³, Belen Villanueva Mañez³, Iago Alcantara Alvarez³, Samuel Leal Rodriguez³, Marta De la Rubia Navarro¹, Ernesto Tovar Sugrañes³, Jose Ivorra Cortes³, Luis Gonzalez Puig³, Rosa Negueroles Albuixech³, Elvira Vicens Bernabeu³, Jose Eloy Oller Rodriguez³, Isabel Martinez Cordellat³, Hikmat Charia³, Ines Canovas Olmos³, Carmen Najera Herranz³ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Valéncia, Spain, ²Rheumatology Department. HUP La Fe, Sagunto, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Herpes zoster infection is due to the reactivation of the varicella-zoster virus (VZV), having a high prevalence in elderly and immunocompromised patients. Since the…
Abstract Number: 0262 • ACR Convergence 2023
Destructive Arthritis in Whipple Disease. a Single-center Case Series of 14 Patients
Xavier Puéchal¹, Philippe Blanche², Olivier Fogel³, Omar Al Tabaa⁴, Roba Ghossan⁴, Xavier Ayral⁴, Jerome AVOUAC⁵, Maxime Breban⁶ and Yannick ALLANORE⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Department of Rheumatology, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁵Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁶Department of Rheumatology, Boulogne-Billancourt, France, ⁷Université Paris Cité, Paris, France
Background/Purpose: Whipple disease is a chronic, curable, systemic bacterial infection caused by Tropheryma whipplei. The classic form usually begins with recurrent arthritis, followed years later…
Abstract Number: 1065 • ACR Convergence 2023
Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs
Ogheneyoma Akpoviroro¹, Nathan Sausers², Oghenetejiro Akpoviroro³, Queeneth Uwandu¹, Myriam Castagne⁴, Elga Rodrigues⁴, Lefulesele Khoalone¹, sara Humayun¹ and Jameson Woodard¹, ¹Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA, ²Pennsylvania State University, State College, PA, ³Mater Dei Hospital, Msida, Malta, ⁴Boston University, Boston, MA
Background/Purpose: Describe patients(pts) hospitalized with COVID-19C(C19) who were on disease modifying antirheumatic drugs (DMARDs) before admission(BA); assess if clinical outcomes differed from pts without BA…
Abstract Number: 1671 • ACR Convergence 2023
Use of Metagenomic Microbial Plasma Cell-Free DNA Next-Generation Sequencing Assay in Outpatient Rheumatology Practice
Rachel Jenkins, Matthew Samec, Courtney Arment and Matthew Koster, Mayo Clinic, Rochester, MN
Background/Purpose: Metagenomic next-generation sequencing (mNGS) of microbial cell-free DNA (mcfDNA) allows for non-invasive broad-range pathogen detection from plasma. The Karius test (KT) is a commercially…
Abstract Number: 2285 • ACR Convergence 2023
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update
J. Patricia Dhar¹, Hannah Forsythe², Louis Saravolatz¹ and Susanna Szpunar³, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Detroit, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St. John Hospital, Detroit, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
Abstract Number: 0200 • ACR Convergence 2023
Herpes Zoster Prevalence in Patients with Rheumatic Diseases
Rodrigo J. Castillo-de la Garza¹, Jorge A. Esquivel-Valerio², Emmanuel Campos-Tinajero², Anahí Carrazco Chapa³, Gisela García Arellano⁴, Axel A. De Leon-Perez², Pablo Gamez-Siller² and Dionicio A. Galarza-Delgado⁵, ¹Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ³Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Herpes zoster (HZ) is a painful rash that is commonly known as shingles. People that had a primary infection caused by the varicella-zoster virus…
Abstract Number: 0295 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia in Patients with Inflammatory Myopathies
Cody Bruggemeyer¹, Sanket Shah², Didem Saygin³ and Mike Putman⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis Jirovecii Pneumonia (PJP) is an opportunistic fungal infection with high morbidity and mortality rates. Few studies to date have assessed the incidence of…
Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Mersine Bryan¹, Jonathan Cogen¹ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children’s Research Institute, Seattle, WA
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…
Abstract Number: 1674 • ACR Convergence 2023
Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group
Benjamin de Valence de Minardiere¹, Marion Delaune², Yann Nguyen³, Vincent Jachiet⁴, Mael Heiblig⁵, Alexis Jean⁶, Pierrick Henneton⁷, stanislas Riescher-tuczkiewicz⁸, Philippe Guilpain⁷, Hervé Lobbes⁹, Guillaume Le Guenno¹⁰, Nicolas Schleinitz¹¹, Valentin Lacombe¹², Vincent Langlois¹³, Roderau Outh¹⁴, Julien Vinit¹⁵, Jean-Philippe Martellosio¹⁶, Paul Decker¹⁷, Alexandre Vlakos¹⁸, Thomas Moulinet¹⁹, Yannick Dieudonne²⁰, Adrien Bigot²¹, Louis Terriou²², Bertrand De Maleprade²³, Guillaume Denis²⁴, Jonathan Broner²⁵, Marie Kostine²⁶, Sébastien Humbert²⁷, Benjamin Terrier²⁸, Sophie Georgin-Lavialle²⁹, Olivier Fain³⁰, Arsène Mekinian¹, Marjolaine MORGAND¹, Thibault Comont² and Jerome Hadjadj¹, ¹Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ²Toulouse University Hospital, Toulouse, France, ³Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ⁴Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France, ⁵Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France, ⁶Internal Medicine Department, Bordeaux University, Faculty of Medicine, Bordeaux University Hospital, Bordeaux, France, ⁷CHU Montpellier, Montpellier, France, ⁸CHU de Nantes, Nantes, France, ⁹CHU de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁰Internal Medicine Department, Clermont-Ferrand University, Faculty of Medicine, Estaing University Hospital, Clermont-Ferrand, France, ¹¹Aix Marseille university, AP-HM, Marseille, France, ¹²Internal Medicine Department, Anger Hospital, Clermont-Ferrand, France, ¹³Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France, ¹⁴Internal Medicine Department, Perpignan Hospital Center, Perpignan, France, ¹⁵Service de Médecine Interne, CH William Morey, Chalon sur Saône, France., Chalon sur Saône, France, ¹⁶Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, ¹⁷Nancy hospital, France, Nancy, France, ¹⁸Vesoul Hospital, Vesoul, France, ¹⁹Department of Internal Medicine, Centre hospitalier universitaire de Nancy, Nancy, France, ²⁰Department of Clinical Immunology and Internal Medicine, National Reference Centre for Systemic Autoimmune Diseases (CNR RESO), Strasbourg University Hospital, Strasbourg, France, ²¹Internal Medicine Department, Tours University, Faculty of Medicine, Tours University Hospital, Tours, France, ²²Service de Médecine Interne et Immunologie Clinique, CHU Lille, Lille, France, ²³Rouen hospital, France, Rouen, France, ²⁴Service d'hématologie, CH de Rochefort, Rochefort, France, ²⁵CHU de Nimes, Nimes, France, ²⁶Bordeaux University Hospital, Bordeaux, France, ²⁷Besançon University Hospital, Besançon, France, ²⁸Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²⁹AP-HP, Tenon hospital, Paris, France, ³⁰Hopital SAINT ANTOINE APHP, Paris, France
Background/Purpose: VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory monogenic disease caused by inactivating somatic mutations in the UBA1 gene and characterized…
Abstract Number: 2293 • ACR Convergence 2023
Recurrent Intracellular Infections Cluster Together in Patients of SLE with Lymphopenia and Active Disease
Rudrarpan Chatterjee¹, Sarit Pattanaik², Durga P Misra¹, Vikas Agarwal¹, Able Lawrence¹, Ramnath Misra³ and Amita Aggarwal¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, India, ³Kalinga Institute of Medical Sciences, KIIT University, Lucknow, India
Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We studied whether infections cluster together and which patients are…
Abstract Number: 0201 • ACR Convergence 2023
Tolerability and Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases – A Prospective Longitudinal Study over 12 Months
Ioana Andreica¹, Gianna Chierergo², Stefania Reale², Benjamin Wilde³, Styliani Tsiami⁴, David Kiefer⁴, Philipp Sewerin⁴, Hilal Kavruk⁵, Dimitra Karagkiozidou², Barbara Guminski⁴, Andreas Kribben³, Xenofon Baraliakos⁶, Juergen Braun⁴ and Uta Kiltz⁷, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Herne, Germany, ³Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁴Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Düsseldorf, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Herpes zoster (HZ) is common in the elderly, with a lifetime risk of 25%. The primary risk factors for HZ are advanced age and…

« Previous Page
1
…
8
9
10
11
12
…
36
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].